Nexalin Technology Inc. - Asset Resilience Ratio
Nexalin Technology Inc. (NXL) has an Asset Resilience Ratio of 40.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Nexalin Technology Inc.'s Asset Resilience Ratio has changed over time. Check NXL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Nexalin Technology Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Nexalin Technology Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 40.62% |
| Total Liquid Assets | $1.50 Million | 40.62% |
Asset Resilience Insights
- Very High Liquidity: Nexalin Technology Inc. maintains exceptional liquid asset reserves at 40.62% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nexalin Technology Inc. Industry Peers by Asset Resilience Ratio
Compare Nexalin Technology Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO |
Medical Devices | 10.80% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Nexalin Technology Inc. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Nexalin Technology Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.20% | $3.07 Million | $4.64 Million | -2.61pp |
| 2024-12-31 | 68.80% | $2.91 Million | $4.22 Million | +3.60pp |
| 2023-12-31 | 65.21% | $2.37 Million | $3.63 Million | -26.71pp |
| 2022-12-31 | 91.91% | $6.83 Million | $7.43 Million | -- |
About Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 a… Read more